Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

Lewczuk P, Riederer P, O'Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR, Teunissen CE, Hampel H, Lleo A, Jessen F, Glodzik L, De Leon MJ, Fagan AM, Luis Molinuevo J, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, Van Doorn LVW, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, Van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Mato AL, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J (2018)

Publication Type: Journal article

Publication year: 2018

Journal

Book Volume: 19

Pages Range: 244-328

Journal Issue: 4

DOI: 10.1080/15622975.2017.1375556

Abstract

In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer's disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, biobanking, analyses and post-analytical interpretation of the results were intensively studied and optimised. A global quality control project was introduced to evaluate and monitor the inter-centre variability in measurements with the goal of harmonisation of results. Contexts of use and how to approach candidate biomarkers in biological specimens other than cerebrospinal fluid (CSF), e.g. blood, were precisely defined. Important development was achieved in neuroimaging techniques, including studies comparing amyloid-β positron emission tomography results to fluid-based modalities. Similarly, development in research laboratory technologies, such as ultra-sensitive methods, raises our hopes to further improve analytical and diagnostic accuracy of classic and novel candidate biomarkers. Synergistically, advancement in clinical trials of anti-dementia therapies energises and motivates the efforts to find and optimise the most reliable early diagnostic modalities. Finally, the first studies were published addressing the potential of cost-effectiveness of the biomarkers-based diagnosis of neurodegenerative disorders.

Authors with CRIS profile

Involved external institutions

Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) Germany (DE) Radboud University Nijmegen Netherlands (NL) University of Paris 6 - Pierre et Marie Curie / Université Paris VI Pierre et Marie Curie (UPMC) France (FR) Washington University United States (USA) (US) State University of New York at Albany (UNY Albany / UAlbany) United States (USA) (US) University of North Texas (UNT) United States (USA) (US) University of Antwerp / Universiteit Antwerpen Belgium (BE) Universität Ulm Germany (DE) Mayo Clinic United States (USA) (US) Rheinische Friedrich-Wilhelms-Universität Bonn Germany (DE) Karolinska Institute Sweden (SE) Universität zu Köln Germany (DE) Universitätsklinikum Würzburg Germany (DE) Maastricht University Netherlands (NL) University of Pennsylvania United States (USA) (US) Medizinische Universität Wien Austria (AT) Georg-August-Universität Göttingen Germany (DE) Paracelsus-Elena-Klinik Kassel Germany (DE) Autonomous University of Barcelona (UAB) / Universitat Autònoma de Barcelona Spain (ES) NYU Langone Medical Center United States (USA) (US) Università degli Studi di Perugia Italy (IT) National Institute on Aging (NIA) United States (USA) (US) Universidad Peruana Cayetano Heredia Peru (PE) Free University Medical Center / VU Medisch Centrum Netherlands (NL) University of Oxford United Kingdom (GB) Sahlgrenska University Hospital / Sahlgrenska Universitetssjukhuset Sweden (SE) Universidad Maimónides Argentina (AR) Hôpital Cochin France (FR) Pasqual Maragall Foundation Spain (ES)

How to cite

APA:

Lewczuk, P., Riederer, P., O'Bryant, S.E., Verbeek, M.M., Dubois, B., Visser, P.J.,... Kornhuber, J. (2018). Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 19(4), 244-328. https://dx.doi.org/10.1080/15622975.2017.1375556

MLA:

Lewczuk, Piotr, et al. "Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry." World Journal of Biological Psychiatry 19.4 (2018): 244-328.

BibTeX: Download